biogen idec
portrait_023.jpg

TYSABRI® (natalizumab) Information Center

2006 TYSABRI® News Archive

Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the approval of TYSABRI® as a Treatment for Crohn's Disease (12/15/2006)

TYSABRI® Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week (10/24/06)

New Pharmacoeconomic Data on TYSABRI® Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis (10/6/06)

New Data Presented at ECTRIMS Congress Show TYSABRI® has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years (9/29/06)

New Data on TYSABRI® Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis (9/28/06)

Biogen Idec and Elan Announce Availability 0f TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis (7/24/06)

TYSABRI® Receives Approval in European Union for the Treatment of Relapsing Remitting Forms of Multiple Sclerosis (6/29/06)

FDA Approves the Reintroduction of TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis (6/5/06)

CHMP Issues Positive Opinion for TYSABRI® as a Treatment for Relapsing-Remitting Multiple Sclerosis (4/27/06)

New Data on TYSABRI® Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients with Multiple Sclerosis (4/6/06)

Biogen Idec and Elan Announce Re-Initiation of TYSABRI® Clinical Trial Dosing in Multiple Sclerosis (3/29/06)

Biogen Idec and Elan Announce that FDA Will Extend Regulatory Review Period for the Reintroduction of TYSABRI® for Multiple Sclerosis (3/22/06)

FDA Advisory Committee Unanimously Recommends Reintroduction of TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis (3/8/06)

TYSABRI® Two-Year Phase III Multiple Sclerosis Clinical Trial Results and Safety Evaluation Published in New England Journal of Medicine (3/1/06)

TYSABRI® Multiple Sclerosis Clinical Trial Hold Lifted by FDA; Biogen Idec and Elan to Resume Clinical Trial Dosing in MS (2/15/06)

Biogen Idec and Elan Announce Notification of FDA Advisory Committee Meeting to Review TYSABRI® for the Treatment of Multiple Sclerosis (1/23/06)


Recent News